Note 9 - Commitments and Contingencies (Details Textual) - USD ($)								1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 22, 2023	Jan. 26, 2023	Nov. 08, 2022	Feb. 07, 2022	Jan. 07, 2022	Jul. 12, 2021	Feb. 28, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 21, 2023	May 11, 2023	Mar. 01, 2023	Dec. 31, 2022	Jun. 30, 2022
Capital Expenditures Incurred but Not yet Paid												$ 4,200,000
Deconsolidation, Gain (Loss), Amount									$ 40,321,483	$ 0		40,321,483	$ 0
Equity Securities, FV-NI	$ 23,996,141								23,996,141			23,996,141					$ 0
Equity Securities, FV-NI, Cost	$ 7,500,000								$ 7,500,000			7,500,000
Special Purpose Acquisition Company (SPAC) [Member]
Financing Receivable, before Allowance for Credit Loss		$ 1,000,000
Murphy Canyon Acquisition Sponsor, LLC [Member]
Intangible Assets, Net (Excluding Goodwill)															$ 5,000,001
Deconsolidation, Gain (Loss), Amount		6,200,000										$ 40,300,000
Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount		$ 34,100,000
Conduit Pharmaceuticals Inc [Member]
Stock Issued During Period, Shares, Acquisitions (in shares)		65,000,000
Stock Issued During Period, Shares, New Issues (in shares)		754,000
Conduit Pharmaceuticals Inc [Member] | Director [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	45,000								45,000			45,000
Stock Issued During Period, Shares, Issued for Services (in shares)	45,000
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		754,000
Conduit Pharmaceuticals Inc [Member] | Conversion of Class B to Class A Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)		3,306,250
Trust for the SPAC Class A Common Stockholders [Member]
Cash Withdrawn From Trust Account											$ 114,100,000
Trust Account, Income Tax Withdraws								$ 200,050
Trust Account, Extension Payments								$ 155,403
Investments											$ 23,300,000							$ 135,100,000
Investment Income, Net												$ 1,200,000	$ 800,000
Annual Yield Return											0.97%
Common Class A [Member]
Stock Redeemed or Called During Period, Shares (in shares)												11,037,272
Stock Subject to Possible Redemption, Shares (in shares)																2,187,728
Stock Issued During Period, Shares, New Issues (in shares)							1,000,000
Common Class A [Member] | Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		754,000
The “Merger Consideration” [Member]
Stock Redeemed or Called During Period, Shares (in shares)			11,037,272
The “Merger Consideration” [Member] | Common Class A [Member]
Stock Issued During Period, Shares, Acquisitions (in shares)				65,000,000
Special Purpose Acquisition Company (SPAC) [Member]
Subsidiary, Ownership Percentage, Parent														65.00%
Conduit Pharmaceuticals Inc [Member]
Investment Owned, Net Assets, Percentage	6.50%								6.50%			6.50%
SPAC, Initial Public Offering [Member] | Murphy Canyon Acquisition Sponsor, LLC [Member]
Proceeds from Issuance of Common Stock					$ 132,250,000	$ 132,250,000
Subsidiary, Ownership Percentage, Parent						23.50%
Units Issued During Period, Units, New Issues (in shares)					13,225,000	132,250,000
SPAC Units, Composition, Number of Shares Per Unit (in shares)						1
SPAC, Placement Units, Number of Units Purchased (in shares)					754,000
SPAC, Placement Units, Price Per Share (in dollars per share)					$ 10
SPAC, Purchase Units, Payments for the Purchase of Equity					$ 7,540,000
Stock Issuance Costs					7,738,161
Underwriting Discounts and Commission					2,645,000
Deferred Underwriting Fees					4,628,750
Other Equity Offering Costs					$ 464,411